Ƶ

Twice-Yearly Schizophrenia Tx OK'd; Austedo Effective Long-Term; $$ for Sobriety

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

The FDA approved the injectable, long-acting atypical antipsychotic , a twice-yearly treatment for schizophrenia in adults who have been adequately treated with the 1- or 3-month versions of paliperidone palmitate, Janssen announced.

And in related news, the FDA accepted a new drug application to review Teva Pharmaceutical and MedinCell's injectable suspension for subcutaneous use (TV-46000/mdc-IRM) as a treatment for schizophrenia, based on the RISE and SHINE studies.

A post-hoc analysis of a 3-year open-label extension study of the showed sustained improvements in the total motor Abnormal Involuntary Movement Scale score in patients of all ages. (American Journal of Geriatric Psychiatry)

Expect a steep spike in as schools begin to reopen. (NPR)

The San Diego City Attorney's Office filed a civil enforcement action , alleging its Mercy Hospital discharged a patient with schizophrenia from one of its hospitals in 2019 despite a court order mandating he be placed in a skilled nursing facility. (Times of San Diego)

California is toying with the idea of to stay sober. (NBC News)

One psychiatrist says , like those induced by taking psychedelic drugs, could come from sources beyond the brain. (iflscience)

A might be one trick to help stave off dementia, according to a study of more than 100,000 individuals. (BMJ)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.